Literature DB >> 9624506

Pharmacokinetic studies of fluconazole in rabbits characterizing doses which achieve peak levels in serum and area under the concentration-time curve values which mimic those of high-dose fluconazole in humans.

A Louie1, Q F Liu, G L Drusano, W Liu, M Mayers, E Anaissie, M H Miller.   

Abstract

We conducted steady-state pharmacokinetic studies with high-dose fluconazole with rabbits and human volunteers. We then derived mathematical equations that predict the doses of fluconazole that should be given to rabbits to produce 24-h area under the concentration-time curve values and maximum concentrations in serum that are similar to those measured for humans given 800 to 2,000 mg of fluconazole per day. These equations provide a rational basis for designing future efficacy studies with rabbits and in evaluating the strength with which results of previously conducted studies using rabbit infection models can be extrapolated to the clinic.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9624506      PMCID: PMC105634     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  14 in total

1.  Pharmacodynamics of fluconazole in a murine model of systemic candidiasis.

Authors:  A Louie; G L Drusano; P Banerjee; Q F Liu; W Liu; P Kaw; M Shayegani; H Taber; M H Miller
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

2.  Pharmacokinetics of fluconazole in cerebrospinal fluid and serum of rabbits: validation of an animal model used to measure drug concentrations in cerebrospinal fluid.

Authors:  A Madu; C Cioffe; U Mian; M Burroughs; E Tuomanen; M Mayers; E Schwartz; M Miller
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

3.  Comparison of itraconazole and fluconazole in treatment of cryptococcal meningitis and candida pyelonephritis in rabbits.

Authors:  J R Perfect; D V Savani; D T Durack
Journal:  Antimicrob Agents Chemother       Date:  1986-04       Impact factor: 5.191

Review 4.  Experimental basis for use of fluconazole for preventive or early treatment of disseminated candidiasis in granulocytopenic hosts.

Authors:  T J Walsh; J Lee; S Aoki; F Mechinaud; J Bacher; J Lecciones; V Thomas; M Rubin; P A Pizzo
Journal:  Rev Infect Dis       Date:  1990 Mar-Apr

Review 5.  Pharmacokinetics and tissue penetration of fluconazole in humans.

Authors:  K W Brammer; P R Farrow; J K Faulkner
Journal:  Rev Infect Dis       Date:  1990 Mar-Apr

6.  Pharmacokinetics and tissue penetration of fluconazole in rabbits.

Authors:  T J Walsh; G Foulds; P A Pizzo
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

7.  Comparison of fluconazole and amphotericin B for treatment of experimental Candida endocarditis caused by non-C. albicans strains.

Authors:  M D Witt; T Imhoff; C Li; A S Bayer
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

8.  Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation--a prospective, randomized, double-blind study.

Authors:  M A Slavin; B Osborne; R Adams; M J Levenstein; H G Schoch; A R Feldman; J D Meyers; R A Bowden
Journal:  J Infect Dis       Date:  1995-06       Impact factor: 5.226

9.  Sensitive bioassay for ketoconazole in serum and cerebrospinal fluid.

Authors:  J H Jorgensen; G A Alexander; J R Graybill; D J Drutz
Journal:  Antimicrob Agents Chemother       Date:  1981-07       Impact factor: 5.191

10.  Safety, plasma concentrations, and efficacy of high-dose fluconazole in invasive mold infections.

Authors:  E J Anaissie; D P Kontoyiannis; C Huls; S E Vartivarian; C Karl; R A Prince; J Bosso; G P Bodey
Journal:  J Infect Dis       Date:  1995-08       Impact factor: 5.226

View more
  16 in total

1.  Antifungal susceptibility testing of fluconazole by flow cytometry correlates with clinical outcome.

Authors:  C Wenisch; C B Moore; R Krause; E Presterl; P Pichna; D W Denning
Journal:  J Clin Microbiol       Date:  2001-07       Impact factor: 5.948

Review 2.  Antifungal susceptibility testing: practical aspects and current challenges.

Authors:  J H Rex; M A Pfaller; T J Walsh; V Chaturvedi; A Espinel-Ingroff; M A Ghannoum; L L Gosey; F C Odds; M G Rinaldi; D J Sheehan; D W Warnock
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

3.  Impact of the order of initiation of fluconazole and amphotericin B in sequential or combination therapy on killing of Candida albicans in vitro and in a rabbit model of endocarditis and pyelonephritis.

Authors:  A Louie; P Kaw; P Banerjee; W Liu; G Chen; M H Miller
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

4.  Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia.

Authors:  Cornelius J Clancy; Victor L Yu; Arthur J Morris; David R Snydman; M Hong Nguyen
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

5.  Efficacies of high-dose fluconazole plus amphotericin B and high-dose fluconazole plus 5-fluorocytosine versus amphotericin B, fluconazole, and 5-fluorocytosine monotherapies in treatment of experimental endocarditis, endophthalmitis, and pyelonephritis due to Candida albicans.

Authors:  A Louie; W Liu; D A Miller; A C Sucke; Q F Liu; G L Drusano; M Mayers; M H Miller
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

6.  Interaction between fluconazole and amphotericin B in mice with systemic infection due to fluconazole-susceptible or -resistant strains of Candida albicans.

Authors:  A Louie; P Banerjee; G L Drusano; M Shayegani; M H Miller
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

7.  Management of invasive candidiasis in the intensive care unit.

Authors:  E Geoffrey Playford; Jeff Lipman; Tania C Sorrell
Journal:  Drugs       Date:  2010-05-07       Impact factor: 9.546

8.  Pharmacodynamic Optimization for Treatment of Invasive Candida auris Infection.

Authors:  Alexander J Lepak; Miao Zhao; Elizabeth L Berkow; Shawn R Lockhart; David R Andes
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

9.  Association of fluconazole pharmacodynamics with mortality in patients with candidemia.

Authors:  John W Baddley; Mukesh Patel; Sujata M Bhavnani; Stephen A Moser; David R Andes
Journal:  Antimicrob Agents Chemother       Date:  2008-06-30       Impact factor: 5.191

Review 10.  Antifungal agents and therapy for infants and children with invasive fungal infections: a pharmacological perspective.

Authors:  Jodi M Lestner; P Brian Smith; Michael Cohen-Wolkowiez; Daniel K Benjamin; William W Hope
Journal:  Br J Clin Pharmacol       Date:  2013-06       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.